Cook's New Brew in AAA Grafts
Sometime in the next year or so, Cook officials hope to enter the market for peripheral vascular grafts for abdominal aortic aneurysms, a highly competitive field currently attracting companies such as Medtronic Inc., Boston Scientific Corp. and Guidant Corrp., which last year purchased AAA leader Endovascular Technologies Inc.
You may also be interested in...
Top management changes at Cook are bringing subtle shifts in the company's attitude towards the marketplace. John DeFord, who has been at the company for 15 years is now president and CEO of its interventional products business, replacing Phyllis McCollough, who moves up to Chairman and EVP of operations for all of Cook Group. DeFord is spearheading Cook's new, more aggressive, opportunistic approach. A noteworthy example: Cook is embarking on a series of distribution deals with a competitor, stent market leader Guidant.
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.